Related Experiment Video
Updated: Nov 5, 2025

Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
Trimethylamine N-Oxide, a Gut Microbiota-Derived Metabolite, Is Associated with Cardiovascular Risk in Psoriasis: A
Mariusz Sikora1, Norbert Kiss2, Albert Stec3
1Department of Dermatology, Medical University of Warsaw, Koszykowa 82a, 02-008, Warsaw, Poland. msikora@wum.edu.pl.
Introduction:
Trimethylamine N-oxide (TMAO), a gut microbiota metabolite from dietary phosphatidylcholine, is involved in the pathogenesis of atherosclerosis and cardiovascular diseases. Psoriasis is associated with increased cardiovascular risk that is not captured by traditional biomarkers. The aim of the present study was to assess TMAO concentration in psoriasis and evaluate the relationship between TMAO and cardiovascular risk in psoriatic patients.
Methods:
In 72 patients with psoriasis and 40 age- and sex-matched non-psoriatic controls, we evaluated fasting plasma TMAO, measured by high-performance liquid chromatography, and cardiovascular risk assessed by various scoring systems such as Framingham, QRISK2, AHA/ACC, and Reynolds risk scores.
Results:
In patients with psoriasis, TMAO concentration was significantly higher than in the control group (195.68 [133.54-332.58] ng/ml versus 126.06 [84.29-156.88] ng/ml, respectively; p < 0.001). Plasma TMAO concentration was significantly correlated with age, total cholesterol, triglycerides, systolic and diastolic blood pressure. Furthermore, the receiver-operating characteristic (ROC) and multiple regression analysis showed that TMAO is an independent predictor of cardiovascular risk.
Conclusion:
TMAO is a valuable candidate for biomarker and a translational link between dysbiosis and atherosclerosis in psoriasis.
Insights
Trimethylamine N-oxide (TMAO) levels are higher in psoriasis patients and independently predict cardiovascular risk, suggesting TMAO as a potential biomarker for atherosclerosis in this population.
Area of Science:
- Metabolomics
- Cardiovascular Research
- Dermatology
Background:
- Trimethylamine N-oxide (TMAO), a gut microbiota metabolite, is implicated in atherosclerosis and cardiovascular diseases.
- Psoriasis patients face elevated cardiovascular risk not fully explained by traditional biomarkers.
Purpose of the Study:
- To measure TMAO concentration in psoriasis patients.
- To investigate the association between TMAO and cardiovascular risk in psoriasis.
Main Methods:
- Evaluated plasma TMAO in 72 psoriasis patients and 40 controls using high-performance liquid chromatography.
- Assessed cardiovascular risk using Framingham, QRISK2, AHA/ACC, and Reynolds risk scores.
Main Results:
- Psoriasis patients exhibited significantly higher TMAO levels compared to controls (195.68 ng/ml vs 126.06 ng/ml).
- TMAO correlated with age, cholesterol, triglycerides, and blood pressure.
- TMAO was identified as an independent predictor of cardiovascular risk.
Conclusions:
- TMAO shows promise as a biomarker for atherosclerosis in psoriasis.
- TMAO may serve as a link between gut dysbiosis and cardiovascular complications in psoriasis.
Related Concept Videos
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Atherosclerosis III: Management
